Proscia will add AI biomarker detection for skin tissue to its Concentriq software platform. Powered by Primaa, Cleo Skin will strengthen Concentriq’s lead in offering the industry’s broadest portfolio of AI solutions on a single platform.
Dermatopathology is among the most diverse areas of pathology, with more than 500 distinct classifications. This variation is compounded by relatively high pathologist disagreement for certain distinctions. While overall inter-observer concordance is estimated at 90–95%, certain distinctions, such as differentiating malignant melanoma from benign melanocytic nevi, can prove challenging.
“This addition underscores our commitment to making AI practical where it can have the greatest impact,” said David West, Proscia’s CEO. “By expanding our AI offerings in skin, we will enable pathologists to deliver faster, more consistent results in one of the most challenging areas of pathology, all within the workflows they trust.”
The AI biomarker detection application automatically identifies all potential mitotic objects and mitotic hotspots as well as perineural invasion, which are key indicators of various skin diseases. In combination with lesion classification, including melanoma, basal cell carcinoma, and squamous cell carcinoma, these capabilities can help drive efficiency. The application also measures tumour margins and lesion dimensions, further driving precise and comprehensive evaluation.
Along with today’s announcement, Primaa will join the Proscia Ready partner alliance. Proscia Ready is made up of solution providers helping life sciences organisations and diagnostic laboratories accelerate the scaled adoption of digital pathology with confidence through a comprehensive approach.
Cleo Skin is not intended for diagnostic use with Concentriq. Contact the original manufacturer for details about indications for use in your region.